title: Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization.
abstract: OBJECTIVE
  To evaluate visual acuity changes and safety of combined treatment with photodynamic therapy (PDT) and intravitreal triamcinolone acetonide (IVTA) in myopic eyes with choroidal neovascularization (CNV).
  
  
  METHODS
  Prospective interventional case series.
  
  
  METHODS
  Twelve eyes of 12 patients with subfoveal myopic CNV were treated with PDT followed by IVTA within a week. Changes in visual acuity and possible complications related to the combined therapy were assessed in periodic visits.
  
  
  RESULTS
  After combined therapy, a significant increase in mean visual acuity was observed at one, three, and six months. A significant increase of mean intraocular pressure was observed after seven days, one month, and three months. Ten patients (83%) required topical antiglaucomatous therapy during follow-up.
  
  
  CONCLUSIONS
  The combination of PDT and IVTA may increase the possibility of improving or stabilizing visual acuity in patients with subfoveal myopic CNV, but further studies are needed to asses the effects of this treatment.
authors.affiliation: Foundation for the Research, Development and Innovation of the University Hospital Complex of Santiago de Compostela (IDICHUS), Santiago de Compostela, Spain. jmarticorena@gmail.com
authors.forename: Joaquin
authors.initials: J
authors.lastname: Marticorena
authors.forename: Francisco
authors.initials: F
authors.lastname: Gomez-Ulla
authors.forename: Maribel
authors.initials: M
authors.lastname: Fernandez
authors.forename: Belen
authors.initials: B
authors.lastname: Pazos
authors.forename: Maria Jose
authors.initials: MJ
authors.lastname: Rodriguez-Cid
authors.forename: Manuel
authors.initials: M
authors.lastname: Sanchez-Salorio
mesh_terms: D000328:Adult; D000368:Aged; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D011166:Porphyrins / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D014222:Triamcinolone Acetonide / Q000009:adverse effects / Q000627:therapeutic use*; D000077362:Verteporfin; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D014222:Triamcinolone Acetonide